jerini ag pharmaceutical company based berlin germany focused discovery development novel peptidebased drugs using proprietary technology platform peptidestodrugs jerini pursued disease indications limited inadequate treatment options exist result jerini established drug pipeline composed programs well others collaboration partners jerinis commercialization strategy market new drugs niche indications independently larger indications partners jerini acquired shire plc jerini started operations jerinis subsidiaries jerini us inc jpt peptide technologies gmbh provider peptides peptide microarrays acquired theracode gmbh mainz jerini financed venture capital provided tvm healthcap went public prime standard frankfurt stock exchange raised total million euro public private financing datecitation needed jerinis lead compound firazyr icatibant inhibitor action hormone bradykinin receptor compound inlicensed aventis approved hereditary angioedema member states european union july drug granted fda approval august based platform jerini established several inhouse development programs address indications within ophthalmology oncology inflammatory therapeutic areas advanced programs targeted agerelated macular degeneration amd leading cause vision loss blindness people age developed countries jerinis compound jsm shown significant efficacy combating disease progression preclinical modelscitation needed jerinis proprietary peptidestodrugs technology used identify peptide drug lead structures systematically transform peptidomimetic injectable smallmolecule oral drugs depending indication enabled jerini develop novel drug candidates diseases difficult access using traditional drug discovery methods ability produce peptidomimetics small molecule drugs drug candidates enabled simultaneous development drugs acute chronic treatments target molecule httpsenwikipediaorgwikijerini